Harnessing the Diversity of Spp. Prophages for Therapeutic Potential

Overview

Journal bioRxiv

Date 2024 Feb 8

PMID 38328162

Authors

Hayley R Nordstrom

Marissa P Griffith

Vatsala Rangachar Srinivasa

Nathan R Wallace

Anna Li

Vaughn S Cooper

Ryan K Shields

Daria Van Tyne

Affiliations

Soon will be listed here.

Abstract

spp. are often resistant to antibiotics, and infections with these organisms are difficult to treat. A potential alternative treatment for spp. infections is bacteriophage (phage) therapy; however, it can be difficult to locate phages that target these bacteria. Prophages incorporated into the bacterial genome have been identified within spp. and may represent a source of useful phages for therapy. Here we investigate whether prophages within spp. clinical isolates can kill conspecific and heterospecific isolates. Thirty-two spp. isolates were induced for prophage release, and harvested prophages were tested for lytic activity against the same 32 isolates. Lytic phages were passaged and their host ranges were determined, resulting in four unique phages of prophage origin that showed different ranges of lytic activity. We also analyzed the prophage content of 35 spp. clinical isolate genomes, and identified several prophages present in the genomes of multiple isolates of the same species. Finally, we observed that isolates were more phage-susceptible than isolates. Overall, our findings suggest that prophages present within spp. genomes are a potentially useful starting point for the isolation and development of novel phages for use in phage therapy.

References

Burns J, Wadsworth C, Barry J, Goodall C . Nucleotide sequence analysis of a gene from Burkholderia (Pseudomonas) cepacia encoding an outer membrane lipoprotein involved in multiple antibiotic resistance. Antimicrob Agents Chemother. 1996; 40(2):307-13. PMC: 163107. DOI: 10.1128/AAC.40.2.307. View

Bondy-Denomy J, Qian J, Westra E, Buckling A, Guttman D, Davidson A . Prophages mediate defense against phage infection through diverse mechanisms. ISME J. 2016; 10(12):2854-2866. PMC: 5148200. DOI: 10.1038/ismej.2016.79. View

Tomasz M . Mitomycin C: small, fast and deadly (but very selective). Chem Biol. 1995; 2(9):575-9. DOI: 10.1016/1074-5521(95)90120-5. View

Seed K, Dennis J . Experimental bacteriophage therapy increases survival of Galleria mellonella larvae infected with clinically relevant strains of the Burkholderia cepacia complex. Antimicrob Agents Chemother. 2009; 53(5):2205-8. PMC: 2681512. DOI: 10.1128/AAC.01166-08. View

OTSUJI N, Sekiguchi M, Iijima T, Takagi Y . Induction of phage formation in the lysogenic Escherichia coli K-12 by mitomycin C. Nature. 1959; 184(Suppl 14):1079-80. DOI: 10.1038/1841079b0. View

Lauman P, Dennis J . Synergistic Interactions among Complex-Targeting Phages Reveal a Novel Therapeutic Role for Lysogenization-Capable Phages. Microbiol Spectr. 2023; 11(3):e0443022. PMC: 10269493. DOI: 10.1128/spectrum.04430-22. View

Bankevich A, Nurk S, Antipov D, Gurevich A, Dvorkin M, Kulikov A . SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol. 2012; 19(5):455-77. PMC: 3342519. DOI: 10.1089/cmb.2012.0021. View

Hancock R . Peptide antibiotics. Lancet. 1997; 349(9049):418-22. DOI: 10.1016/S0140-6736(97)80051-7. View

Dedrick R, Guerrero-Bustamante C, Garlena R, Russell D, Ford K, Harris K . Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat Med. 2019; 25(5):730-733. PMC: 6557439. DOI: 10.1038/s41591-019-0437-z. View

10.

Aslam S, Courtwright A, Koval C, Lehman S, Morales S, Furr C . Early clinical experience of bacteriophage therapy in 3 lung transplant recipients. Am J Transplant. 2019; 19(9):2631-2639. PMC: 6711787. DOI: 10.1111/ajt.15503. View

11.

Al-Anany A, Fatima R, Hynes A . Temperate phage-antibiotic synergy eradicates bacteria through depletion of lysogens. Cell Rep. 2021; 35(8):109172. DOI: 10.1016/j.celrep.2021.109172. View

12.

Jones A, Dodd M, Webb A . Burkholderia cepacia: current clinical issues, environmental controversies and ethical dilemmas. Eur Respir J. 2001; 17(2):295-301. DOI: 10.1183/09031936.01.17202950. View

13.

Jain C, Rodriguez-R L, Phillippy A, Konstantinidis K, Aluru S . High throughput ANI analysis of 90K prokaryotic genomes reveals clear species boundaries. Nat Commun. 2018; 9(1):5114. PMC: 6269478. DOI: 10.1038/s41467-018-07641-9. View

14.

Weiser R, Yap Z, Otter A, Jones B, Salvage J, Parkhill J . A Novel Inducible Prophage from G4 is Widely Distributed across the Species and Has Lytic Activity against Pathogenic . Viruses. 2020; 12(6). PMC: 7354579. DOI: 10.3390/v12060601. View

15.

Dedrick R, Jacobs-Sera D, Guerrero Bustamante C, Garlena R, Mavrich T, Pope W . Prophage-mediated defence against viral attack and viral counter-defence. Nat Microbiol. 2017; 2:16251. PMC: 5508108. DOI: 10.1038/nmicrobiol.2016.251. View

16.

Roszniowski B, Latka A, Maciejewska B, Vandenheuvel D, Olszak T, Briers Y . The temperate Burkholderia phage AP3 of the Peduovirinae shows efficient antimicrobial activity against B. cenocepacia of the IIIA lineage. Appl Microbiol Biotechnol. 2016; 101(3):1203-1216. PMC: 5247547. DOI: 10.1007/s00253-016-7924-7. View

17.

Zahariadis G, Levy M, Burns J . Cepacia-like syndrome caused by Burkholderia multivorans. Can J Infect Dis. 2007; 14(2):123-5. PMC: 2094916. DOI: 10.1155/2003/675159. View

18.

Stamatakis A . RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies. Bioinformatics. 2014; 30(9):1312-3. PMC: 3998144. DOI: 10.1093/bioinformatics/btu033. View

19.

Oliveira J, Mahony J, Hanemaaijer L, Kouwen T, Neve H, MacSharry J . Detecting Prophages by Mitomycin C-Mediated Induction Coupled to Flow Cytometry Analysis. Front Microbiol. 2017; 8:1343. PMC: 5515857. DOI: 10.3389/fmicb.2017.01343. View

20.

Arndt D, Marcu A, Liang Y, Wishart D . PHAST, PHASTER and PHASTEST: Tools for finding prophage in bacterial genomes. Brief Bioinform. 2017; 20(4):1560-1567. PMC: 6781593. DOI: 10.1093/bib/bbx121. View